Top ▲

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Acute pancreatitis

GtoPdb Disease Summaries

This section gives an overview of the disease, and where available shows the following:

  • Synonyms: Shows known synonyms for the disease.
  • Description: Gives a basic description/definition of the disease.
  • Database Link: External links to the same disease at the Disease Ontology, OMIM or Orphanet sites.
  • Immunopharmacology comments: General comments about the target's role in immunopharmacology, provided by GtoImmuPdb curators.
  • Associated with: Counts are displayed for the total targets the disease is associated with in GtoPdb. The counts of targets and ligands of immunological relevance associated to the disease are also shown.

More information can be found in the help pages.

✖
Disease ID:1261
Name:Acute pancreatitis
Associated with:0 target
1 immuno-relevant ligand
Description
A sudden inflammation of the pancreas that is commonly caused by gallstones or alcohol abuse.

Targets

GtoPdb Disease Summaries - Targets

Click on the target name to link to its detailed view page

Where available, information is display on the role of the target in the disease; drugs which target the disease and their therapeutic use and side-effects.

If there is mutation data curated in GtoPdb this is indicated, with a link back to the appropriate section on the target detailed view page

Immuno ligand interactions - If available, a table of immuno-relevant ligands is shown. These ligands have been curated as having an association to the disease and possess interaction data with the target in GtoPdb. The approval status of the ligand is shown, along with curator comments and an indication of whether the target is considered the primary target of the ligand.

More information can be found in the help pages.

✖
Key to terms and symbols

No target related data available for Acute pancreatitis

Ligands

GtoPdb Disease Summaries - Ligands

Click ligand name to view ligand summary page

  • Approved: If the ligand is an approved drug this is indicated, along with approval bodies.
  • Immuno: Immuno icon indicates the ligand is immuno-relevant

Click the arrow in the final column to expand comments

  • Immuno Disease Comments: Curatorial comments specifically added as part of GtoImmuPdb. They give more information on the association between the ligand and disease in the context of immunopharmacology.
  • Clinical Use: General clinical comments relating to the ligand and may not necessarily be specific to the disease in question. With hyperlink to more details on the ligand summary pages.
  • Bioactivty Comments: Curatorial comments specifically about the compounds biological activity - with hyperlink to more details on the ligand summary pages.

More information can be found in the help pages.

✖
Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
zegocractin
Immuno Disease Comments: Phase 2 clinical candidate for the treatment of acute pancreatitis- see NCT03401190
Clinical Use: Zegocractin (CM4620) is a therapeutic lead compound that is in clinical trial. It is proposed to target calcium overload- driven pancreatic injury and inflammation in patients with asparaginase-associated pancreatitis [1]. It was tested in patients with acute/critical COVID-19 pneumonia. | View clinical data
Bioactivity Comments: Preclinical results indicate that inhibition of Orai1 reduces calcium-induced injury to human and mouse pancreatic acinar cells in vitro, and to whole pancreas in mouse models [2]. | View biological activity

References

Show »

1. Lewis S, Evans DL, Tsugorka TT, Peng S, Stauderman K, Gerasimenko O, Gerasimenko J. (2024) Combination of the CRAC Channel Inhibitor CM4620 and Galactose as a Potential Therapy for Acute Pancreatitis. Function (Oxf), 5 (4). [PMID:38984998]

2. Wen L, Voronina S, Javed MA, Awais M, Szatmary P, Latawiec D, Chvanov M, Collier D, Huang W, Barrett J et al.. (2015) Inhibitors of ORAI1 Prevent Cytosolic Calcium-Associated Injury of Human Pancreatic Acinar Cells and Acute Pancreatitis in 3 Mouse Models. Gastroenterology, 149 (2): 481-92.e7. [PMID:25917787]